Nexalin Technology, Inc. (NXL)

Market Cap	19.41M
Revenue (ttm)	131,065
Net Income (ttm)	-8.55M
Shares Out	17.18M
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,042
Open	1.160
Previous Close	1.190
Day's Range	1.115 - 1.180
52-Week Range	0.591 - 4.490
Beta	4.05
Analysts	Strong Buy
Price Target	5.00 (+342.48%)
Earnings Date	Aug 7, 2025

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3 headset devices, that is in clinical trials for the treatment of post-traumatic stress disorder, traumatic brain injury, and substance use disorder issues related to opiate, alcoholism and chronic pain, alzheimer’s disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive, safe and virtually undet...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 16, 2022
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: NXL
• Website: https://www.nexalin.com

Financial Performance

In 2024, Nexalin Technology's revenue was $168,721, an increase of 52.35% compared to the previous year's $110,748. Losses were -$7.61 million, 63.6% more than in 2023.

Analyst Forecast

According to one analyst, the rating for NXL stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(342.48% upside)

Analyst Consensus: Strong Buy